An additional factor related with changes in the expression of adaptive NK cell markers in MS was IFNβ therapy, which was associated with reduced proportions of CD56dim FcRγ(–) NK cells in HCMV(+) RRMS patients. This evidence concerns the gene FCER1G and myeloid sarcoma.